Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from an ACTH(4-7) fragment extended by Pro-Gly-Pro. It has been examined in lab settings for effects on neural pathways and enzyme interactions, and its sequence/chemistry are well described in the peptide literature.
Key research notes
- Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from an ACTH(4-7) fragment extended by Pro-Gly-Pro.
- It has been examined in lab settings for effects on neural pathways and enzyme interactions, and its sequence/chemistry are well described in the peptide literature.
- N-Acetyl Semax Amidate (often written Ac-Semax-NH₂) features the same seven-amino-acid backbone as Semax but with N-terminal acetylation and C-terminal amidation.
N-Acetyl Semax Amidate (often written Ac-Semax-NH₂) features the same seven-amino-acid backbone as Semax but with N-terminal acetylation and C-terminal amidation. These terminal caps are common peptide modifications explored to affect stability and handling in experimental systems.
Backbone: Identical sequence (MEHFPGP). Termini: Semax has free N- and C-termini; N-Acetyl Semax Amidate is acetylated (N-cap) and amidated (C-cap), a change often investigated to influence enzymatic susceptibility and physicochemical behavior in assays.
How Have They Been Studied in Research? Semax (foundational studies): Early work characterized sequence, enzyme sensitivity, and degradation pathways in blood/serum, indicating prominent roles for aminopeptidases in N-terminal cleavage of Semax and related fragments.
(link 2) N-Acetyl Semax Amidate (terminally modified analog): Acetylating Semax's N-terminus alters metal-ion coordination and downstream properties in vitro; this has been used as a model to study how terminal capping can change peptide behavior in cell and coordination assays. Delivery/stability context (literature overview): Reviews of intranasal peptide research and peptide-delivery strategies note terminal modifications (including N-acetylation) and formulation approaches as ways to explore stability during experimental handling; some reports specifically mention acetylated Semax among promising candidates for such work.
Advantages in Laboratory Context Defined Backbone With a Well-Documented Parent Peptide Semax's sequence and degradation pathways are described across multiple studies, providing a clear baseline for comparative experiments. (link 2) Terminal Modifications Enable Controlled Comparisons Using N-Acetyl Semax Amidate allows researchers to isolate the impact of capping on coordination chemistry or assay stability without changing the primary sequence.
Method Development Reviews highlight terminal modification as one of several knobs (alongside carriers and excipients) for exploring peptide handling and recovery in in vitro or model-delivery setups. Limitations to Keep in Mind Enzymatic Susceptibility (Parent Peptide): Semax is susceptible to aminopeptidases and other enzymes; experimental design often accounts for this during incubations or biological-media exposure.
(link 2) Altered Interactions (Modified Analog): N-terminal acetylation can change metal-binding modes and related readouts, so results may diverge from the parent peptide in specific assays. Heterogeneous Literature Footing: Semax has a longer publication history than its acetyl-amidated analog; direct head-to-head datasets are comparatively limited in the public literature.
References
- Influence of the N-terminus acetylation of Semax (ACTH(4-10) analog) on copper(II) and zinc(II) coordination and biological properties.
- N-terminal degradation of ACTH(4-10) and its synthetic analog Semax by rat blood enzymes.
- Biochemical and Biophysical Research Communications.
- Degradation of ACTH/MSH(4-10) and its synthetic analog Semax by rat serum enzymes: an inhibitor study.
- Effect of modification of the N-terminal region of Semax on the expression of nootropic effect of Semax analogs.
The statements made on this website have not been evaluated by the Food and Drug Administration, the products offered are not intended to diagnose, treat, cure, or prevent any disease, AssayGrade Peptides is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, and all products are sold strictly for research purposes only and are not for human or animal consumption.